Treatment of chronic proliferative cholangitis with c-myc shRNA

Figure 1 HE staining and immunohistochemistry for c-myc in CPC group (A, D), c-myc shRNA-3 treatment group (B, E), and c-myc shRNA-2 treatment group (C, F). Briefly, treatment with c-myc shRNA, especially with c-myc shRNA-3, can efficaciously inhibit hyperplasia of biliary epithelium, submucosal gland, collagen fiber, and down-regulate c-myc expression (A-C, × 50; D-F, × 100).

Figure 2  Real-time PCR (A) and Western blot (B) analysis of c-myc and PCNA expression in biliary duct wall.

Figure 3 Immunofluorescence (A, B) and RT-PCR (C) analysis of mucin 5AC in bile duct wall. CPC group (A), c-myc shRNA-3 treatment group (B). Briefly, treatment with c-myc shRNA-3 can result in a more prominent down-regulation of mucin 5AC expression (A and B, × 400).

Figure 4 Enzymatic histochemistry staining of endogenous β-G (cryostat section,× 400) in CPC group (A) and c-myc shRNA-3 treatment group (B). A notable reduction of endogenous β-G was observed in the bile duct wall following c-myc shRNA treatment.

Figure 5 Western blot analysis of procollagen III expression in biliary duct wall.